NovaBridge Biosciences

What they do

The company operates in pharmaceutical preparations (SIC 2731) and files with the SEC as a foreign private issuer on Form 20-F. Its latest annual report for the fiscal year ended December 31, 2025 was amended on June 16, 2026 solely to correct beneficial ownership information. The available filing excerpts do not describe specific products, pipeline programs or commercial operations.

Revenue drivers

• Total revenue — Reported annual revenue was $4.3M in 2019, $236.4M in 2020, $13.8M in 2021, negative $1.6M in 2022 and $632,000 in 2023; the excerpts do not break revenue into segments or product lines.
• Historical revenue volatility — The swing from $236.4M in 2020 to $632,000 in 2023, with a negative $1.6M in 2022, indicates revenue is not recurring on a stable base, but the source material does not attribute this to specific products or contracts.
• Net loss trend — Net losses were $365.9M in 2021, $371.1M in 2022, $207.7M in 2023, $22.2M in 2024 and $46.3M in 2025, with the 2025 widening versus 2024.

Recent performance

For fiscal 2025, NovaBridge reported a net loss of $46.3M and diluted EPS of -$0.21, compared with a $22.2M net loss and -$0.12 EPS in 2024. Operating cash outflow was $20.6M in 2025, an improvement from $52.7M in 2024 but still negative. At December 31, 2025, total assets were $260.5M, total liabilities $29.6M, shareholder equity $230.9M and cash and equivalents $210.6M. No revenue figure for 2024 or 2025 appears in the provided financial data.

Strategy

The only filing excerpt provided is Amendment No. 1 to the 2025 Form 20-F, filed to correct beneficial ownership information, and it states the correction does not affect the audited financial statements. The amendment re-executes Section 302 and Section 906 certifications and otherwise does not update the original filing for events after April 7, 2026. No strategy, pipeline or capital allocation discussion is included in the available excerpts.

Risks

• Persistent losses — NovaBridge has reported net losses in each year from 2021 through 2025, including $46.3M in 2025, and negative operating cash flow in every year shown.
• Erratic revenue — Revenue has ranged from $236.4M in 2020 to $632,000 in 2023 and negative $1.6M in 2022, showing no stable earnings base.
• Cash burn — Operating cash outflow totaled $20.6M in 2025, and the company held $210.6M in cash and equivalents at December 31, 2025 against a $29.6M liability balance.
• Limited disclosure in the provided excerpts — The only filing text supplied is an ownership-correction amendment, so product, pipeline and customer concentration risks cannot be assessed from the available material.

Outlook

The provided excerpts contain no management outlook, guidance or forward-looking operating commentary. The only forward statement is that the June 16, 2026 amendment does not reflect events occurring after the original filing was filed on April 7, 2026.